<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5262">
  <stage>Registered</stage>
  <submitdate>5/11/2015</submitdate>
  <approvaldate>5/11/2015</approvaldate>
  <nctid>NCT02616445</nctid>
  <trial_identification>
    <studytitle>Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects</studytitle>
    <scientifictitle>A Phase I Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UE2343 in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACW0001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - UE2343
Treatment: drugs - Placebo
Treatment: drugs - Placebo
Treatment: drugs - UE2343
Treatment: drugs - UE2343

Placebo Comparator: MAD Study - 

Placebo Comparator: Fed-Fasted - 

Experimental: CSF - 


Treatment: drugs: UE2343
UE2343
10mg, 20, 35mg
twice daily for 9 days

Treatment: drugs: Placebo
10mg, 20, 35mg
twice daily for 9 days

Treatment: drugs: Placebo
Cross-over study
single dose administered twice (on day 1 and day 8)
study duration 17 days

Treatment: drugs: UE2343
Cross-over study
UE2343
single dose administered twice (on day 1 and day 8)
study duration 17 days

Treatment: drugs: UE2343
UE2343
twice daily for 3 days
single dose on day 4

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess Safety and Tolerability of UE2343 over 17 days including AEs, 12-lead ECGs, vital signs, Nerve conduction velocity, Labs.</outcome>
      <timepoint>Up to Day 17</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess the Pharmacokinetic (PK) Plasma Parameter Maximum Plasma Concentration (Cmax) of UE2343 after a single dose</outcome>
      <timepoint>Day 1 and Day 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess the Pharmacokinetic (PK) Plasma Parameter Time to Cmax (Tmax) of UE2343 after a single dose</outcome>
      <timepoint>Day 1 and Day 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess the Pharmacokinetic (PK) Plasma Parameter Area Under the Curve (AUC) of UE2343 after a single dose</outcome>
      <timepoint>Day 1 and Day 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess the Pharmacokinetic (PK) Plasma Parameter Terminal Elimination Half Life (t½) of UE2343 after a single dose</outcome>
      <timepoint>Day 1 and Day 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess PK Parameter Maximum Plasma Concentration (Cmax) of UE2343 in CSF</outcome>
      <timepoint>Day 4</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacokinetics (PK) Plasma parameter Maximum Plasma Concentration (Cmax) from time of dosing to 12 hours</outcome>
      <timepoint>Day 1 and Day 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacokinetics (PK) Plasma parameter Time to Cmax (Tmax) from time of dosing to 12 hours</outcome>
      <timepoint>Day 1 and Day 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacokinetics (PK) Plasma parameter Area Under the Curve (AUC) from time of dosing to 12 hours</outcome>
      <timepoint>Day 1 and Day 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacokinetics (PK) Plasma parameter Terminal Elimination Half Life (t½) from time of dosing to 12 hours</outcome>
      <timepoint>Day 1 and Day 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacokinetics (PK) Urine parameters (Amount of drug excreted in urine (Ae) and Ae as a % of dose) from time of dosing to 24 hours</outcome>
      <timepoint>Day 1 and Day 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess PK Parameter Maximum Plasma Concentration (Cmax) of UE2343 in CSF compared to the Cmax value obtained in plasma</outcome>
      <timepoint>Day 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Blood parameter Adrenocorticotropic hormone (ACTH) from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11, 12, 13 and 17.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Blood parameter Serum Cortisol from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11, 12, 13 and 17.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Blood parameter for Adrenal Androgens from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11, 12, 13 and 17.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Urine parameter Urinary Free Cortisol (UFF) from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Urine parameter Urinary Free Cortisone (UFE) from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Urine parameter 5a-tetrahydrocortisol (5aTHF) from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Urine parameter 5ß-tetrahydrocortisol (5ßTHF) from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11 and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess Pharmacodynamics (PD) Urine parameter tetrahydrocortisone (THE) from baseline to end of study</outcome>
      <timepoint>Days 1, 10, 11 and 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Willing to use specified contraception

          -  BMI within specified range

          -  No clinically significant abnormalities in the results of laboratory evaluations at
             Screening and Day -1.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Abnormal medical history, including history of dementia

          -  No significant allergic reactions

          -  No prior drug or alcohol abuse

          -  Use of regular prescribed medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Linear Clinical Research - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Actinogen Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novotech (Australia) Pty Limited</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Linear Clinical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether the drug UE2343, a potential treatment for
      Alzheimer's Disease (AD), is effective by assessing safety, tolerability, pharmacokinetics
      and pharmacodynamics in a Multiple Ascending Dose Study. Protocol amendments to the study
      will examine any food effect and determine if the drug penetrates the Blood-Brain Barrier.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02616445</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Vincent Ruffles</name>
      <address>Actinogen Medical</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>